Inscription à l’infolettre

Publications

Publications récentes

Voir les publications précédentes
  • 1er novembre 2017

    WD40 repeat domain proteins: a novel target class?

    Schapira M, Tyers M, Torrent M, Arrowsmith CH
    Nat Rev Drug Discov 2017-11-01 ;16( 11 ):773-786

  • 1er novembre 2017

    PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers.

    Chen L, Yuan Y, Kar S, Kanchi MM, Arora S, Kim JE, Koh PF, Yousef E, Samy RP, Shanmugam MK, Tan TZ, Shin SW, Arfuso F, Shen HM, Yang H, Goh BC, Park JI, Gaboury L, Lobie PE, Sethi G, Lim LHK, Kumar AP
    Mol. Cancer Ther. 2017-11-01 ;16( 11 ):2528-2542

  • 1er novembre 2017

    UBAP2L is amplified in a large subset of human lung adenocarcinoma and is critical for epithelial lung cell identity and tumor metastasis.

    Aucagne R, Girard S, Mayotte N, Lehnertz B, Lopes-Paciencia S, Gendron P, Boucher G, Chagraoui J, Sauvageau G
    FASEB J. 2017-11-01 ;31( 11 ):5012-5018

  • 31 octobre 2017

    RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition.

    Jin T, Lavoie H, Sahmi M, David M, Hilt C, Hammell A, Therrien M
    Nat Commun 2017-10-31 ;8( 1 ):1211

  • 24 octobre 2017

    Mass Cytometric Analysis Reveals Viable Activated Caspase-3+ Luminal Progenitors in the Normal Adult Human Mammary Gland.

    Knapp D, Kannan N, Pellacani D, Eaves CJ
    Cell Rep 2017-10-24 ;21( 4 ):1116-1126

  • 23 octobre 2017

    Evolution of AF6-RAS association and its implications in mixed-lineage leukemia.

    Smith M, Ottoni E, Ishiyama N, Goudreault M, Haman A, Meyer C, Tucholska M, Gasmi-Seabrook G, Menezes S, Laister RC, Minden MD, Marschalek R, Gingras AC, Hoang T, Ikura M
    Nat Commun 2017-10-23 ;8( 1 ):1099

  • 17 octobre 2017

    Revealing the Determinants of Widespread Alternative Splicing Perturbation in Cancer.

    Li Y, Sahni N, Pancsa R, McGrail DJ, Xu J, Hua X, Coulombe-Huntington J, Ryan M, Tychhon B, Sudhakar D, Hu L, Tyers M, Jiang X, Lin SY, Babu MM, Yi S
    Cell Rep 2017-10-17 ;21( 3 ):798-812

  • 19 septembre 2017

    HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma.

    Matsuda H, Campion CG, Fujiwara K, Ikeda J, Cossette S, Verissimo T, Ogasawara M, Gaboury L, Saito K, Yamaguchi K, Takahashi S, Endo M, Fukuda N, Soma M, Hamet P, Tremblay J
    Oncotarget 2017-09-19 ;8( 41 ):69559-69576

Voir plus de publications